Ingenza, a world-leading protein CRDMO – recently welcomed key customers, partners, associates and colleagues to celebrate the official naming and inauguration of its state-of-the-art facility, the inGenius® Building.
The relocation follows a strategic review of the company’s long-term development plans, and the bespoke, multi-million-pound inGenius® Building is designed to more than double Ingenza’s operational footprint, significantly increase capacity across all service areas and strengthen the company’s ability to deliver flexible, scalable solutions to its growing customer base. The innovative design will allow Ingenza to scale up manufacturing to 100 L, paving the way for the production of cGMP clinical material.
The celebratory afternoon featured guided lab tours and a technology showcase culminating in an official ribbon cutting ceremony led by President and Founder Dr. Ian Fotheringham MBE alongside key Ingenza partners, Jenny Forbes, North American Vice President of Phibro Ethanol and Alain Townsend, Professor Emeritus of Molecular Immunology at Oxford University.
Ian commented on the event,
“It was a terrific afternoon celebrating this momentous milestone for Ingenza and fantastic to jointly cut the ribbon with Jenny Forbes from Phibro Ethanol US, one of our most valued customers and partners since 2017 and Alain Townsend from Oxford University who has been highly influential to Ingenza’s subunit-vaccine development work.”.
Dr. Nick Challoner, CEO of Ingenza described the event,
“Our celebratory afternoon with our key customers and partners was a great success and I echo the words that I used in my speech that together, we can accelerate the delivery of solutions in Human & Animal Health and Sustainable Technologies. Together, we can build new partnerships, expand our impact, and create lasting value. And together, we can ensure that the next chapter of Ingenza’s story is every bit as successful as those that came before it”.